Advanced in Osteosarcoma

Frank M. Speetjens

Leiden, ZH, NL 
Advanced in Osteosarcoma
Leiden, ZH, NL 
OverviewLocationsClinical Research

Overview

Frank Speetjens practices in Leiden, Netherlands. Mr. Speetjens is rated as an Advanced expert by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Uveal Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Adult Soft Tissue Sarcoma.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Osteosarcoma.

Gender
Male

Locations

Leiden, ZH, Netherlands
Other Locations
Leiden Universitair Medisch Centrum, Leiden
Zuideinde, OV, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma
Phase1b/2 Study Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab and Nivolumab, Melphalan Chemosaturation via Percutaneous Hepatic Perfusion
Study Phase: Phase 1/Phase 2

39 Total Publications

Correction: Kalisvaart et al. Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study. Cancers 2024, 16, 1954.
Correction: Kalisvaart et al. Relative Wash-In Rate in Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a New Prognostic Biomarker for Event-Free Survival in 82 Patients with Osteosarcoma: A Multicenter Study. Cancers 2024, 16, 1954.
Journal: Cancers
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Speetjens's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile